[1] Kainuma M, Fujimoto M, Sekiya N, et al.Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis[J]. J Gastroenterol, 2006,41(10):971-980.
[2] Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity[J]. J Clinl Endocrinol Metab, 2005, 90(6) :3498-3504.
[3] Zhou MY, Xu AM,Tam PKH, et al. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury[J]. HEPATOLOGY, 2008, 48(4): 1087-1096.
[4] You M, Matsumoto M,Pacold CM,et al.The role of AMP-activated protein kinaseinthe action of ethanol in the liver[J]. Crastepoenterology,2004, 127(6): 1798-1808.
[5] Yamauchi T,Kamon J,Ito Y,et al.Cloning of adiponectin receptors that mediate antidiabetic metabolic effects[J]. Nature, 2003,423(6941):762-769.
[6] Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30[J]. J Clin Invest, 2001,108(13):1875-1881.
[7] Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin[J]. Gastroenterology, 2003, 125(6) :1796-1807.
[8] 于丹,马红.脂联素随原代HSC 活化表达的动态变化及其对原代HSC 表达MMP-13的影响[J].世界华人消化杂志, 2007,15(36):3793-3797.
[9] Hu ZW, Guo JW, Deng XL.Association of serum leptin and insulin resistance with nonalcoholic fatty liver disease[J].Nan Fang Yi Ke Da Xue Xue Bao, 2006, 26(6):853-855.
[10] Huang XD, Fan Y, Zhang H, et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2008,14(18):2888-2893.
[11] Shivakumar C, Geoffrey, Linda F, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity[J]. Hepatology, 2002,36(2):403-409.
[12] Saxena NK, Ikeda K, Rockey DC,et al. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice[J]. Hepatology, 2002,35(4):762-771.
[13] Qamar A, Sheikh SZ, Masud A, et al. In vitro and in vivo protection of stellate cells from apoptosis by leptin[J]. Dig Dis Sci, 2006,51(10):1697-1705.
[14] Elinav E, Ali M, Bruck R,et al. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function[J]. Hepatology, 2009,49(1):278-286.
[15] Gove ME, Rhodes DH, Pini M, et al. Role of leptin receptor-induced STAT3 signaling in modulation of intestinal and hepatic inflammation in mice[J]. J Leukoc Biol, 2009,85(3):491-496.
[16] Steppan CM, Bailley ST, Bhat S, et al. The hormone resistin links obesity to diabetes[J]. Nature, 2001,409(6818):307.
[17] 饶绍琴,邓君,陈述,等.非酒精性脂肪肝患者血清抵抗素与胰岛素抵抗关系的探讨[J]. 中国实验诊断学, 2008,12(8):1024-1026.
[18] Muse ED, Obici S, Bhanot S, et al.Role of resistin in diet-induced hpatic insulin resistance[J]. J Clin Invest, 2004,114(2):232-239.
[19] Pagano C, Soardo G, Pilon C, et al.Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance[J]. J Clin Endocrinol Metab, 2006,91(3):1081-1086.
[20] 赵和平,杨文慧,段晓燕,等.动态观察非酒精性脂肪肝大鼠肝脏抵抗素的表达[J]. 国际内科学杂志, 2007,34(11):628-631.
[21] Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin[J]. Science, 2005,307(5708):426-430.
[22] Atsunori F, Morihiro M, Masako N, et al. Visfatin: a protein secreted by visceral fat thatmimics the effects of insulin[J]. Science, 2005,307(5708):426-430.
[23] Li L, Yang G, Shi S, et al.The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo[J]. Cytokine, 2009,45(1):12-19.
[24] Murphy KG, Bloom SR. Are all fats created equa[J]? Nat Med, 2006,12(1):32-33.
[25] Johansson LM, Johansson LE, Ridderstrle M.The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects[J]. Metabolism, 2008,57(11):1558-1562.
[26] Aller R, de Luis DA, Izaola O, et al.Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease[J]. Dig Dis Sci, 2009,54(8):1772-1777.
[27] Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice[J]. Cell Metab, 2008,8(5):437-445.
[28] Pérez-Echarri N, Pérez-Matute P, Marcos-Gómez B, et al. Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats[J]. Br J Nutr, 2009,101(7):1059-1067.
[29] 魏丽,贾伟平,吴海娅,等.肥胖及2型糖尿病患者血清apelin水平及其相关因素分析[J]. 中华内分泌代谢杂志, 2007,23(2):130-133.
[30] Principe A, Melgar-Lesmes P, Fernández-Varo G, et al. The hepatic apelin system: a new therapeutic target for liver disease[J]. Hepatology, 2008,48(4):1193-1201.
[31] Bekri S, Gual P, Anty R, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH[J]. Gastroenterology, 2006,131(3):788-796.
[32] Barisani D, Pelucchi S, Mariani R, et al.J Hepatol. Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload[J]. 2008,49(1):123-133.
[33] Hsiao TJ, Chen JC, Wang JD.Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients[J]. Int J Obes Relat Metab Disord, 2004,28(1):167-172.
[34] Mitsuyoshi H, Yasui K, Harano Y, et al. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease[J]. Hepatol Res, 2009,39(4):366-373.
[35] Wurm S, Neumeier M, Weigert J, et al. Plasma level s of leptin, omentin, collagenous repeat-containing sequence of 26-kDa protein (CORS-26) and adiponectin before and after oral glucose uptake in slim adults[J]. Cardiovasc Diabetol Cardiovasc Diabetol, 2007,6:7.
[36] Kalra SP. Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions[J]. Peptides, 2008,29(1):127-138. |
